HKUMed SCAN 2030

Methodology

Leadership

Action Team

Project Background

While Hong Kong is renowned for its advanced public healthcare system, it faces the heavy healthcare burden brought by the aging population. From 2020 to 2022, there are around 60 to 90 drugs with new chemical entities approved annually. Considering the rapid advancement of medical technology and the increasing availability of therapies to address diverse health needs, it is crucial to strike a balance between the costs and benefits of new medicines. This balance becomes particularly important for patients with aging and non-communicable diseases that place a long-term burden on the healthcare system. To address this challenge, a comprehensive approach such as Health Technology Assessment (HTA) mechanism is potentially beneficial.

Project Objectives

SCAN-2030 aims to establish a living pipeline of global innovative medicines and the prioritization criteria for facilitating and optimizing the decision-making process. SCAN-2030 has three interlinked packages:

1

Territory-wide electronic medical records to assess

                            Current disease burden
Medication use pattern
Unmet needs in the innovative medicines

2

AI and Simulation Modelling to project

                            Population-specific 10-year disease burden
Care needs

3

Global and local-evidence-based decision-analytic modelling to evaluate

                            Cost-effectiveness
Return-on-investment
Budget impact of introducing innovative medicine

Project Highlights

Integrated Digital Toolkits to Inform Policy

Innovative Medicine Database

A drug bank crafted by biomedical experts to include the latest research and discovery needs

Simulation Modeling for Disease Burden Forecasting

A project-specific website for SCAN-2030 to visualise the up-to-date results, engage multiple stakeholders and provide knowledge exchange platform for impact creation

Infographics for Therapeutic Areas and Innovative Medicines

Decision-assistance toolkits for innovative medicines using layman language-based leaflets and interactive output illustrations

HEOR 101 Online Lecture Series

Bite-sized videos to explain the essential concepts of innovative medicines

Knowledge Exchange and Publicity

Patient educational symposiums, seminars, round-table discussion, and workshops to understand the unmet needs and barriers of using innovative medicines from patient perspectives

Voice of Patients and Stakeholders Feedback on HTA

Systematic collection and analysis of feedback from multiple stakeholders